表紙
市場調查報告書

A型肝炎病毒細胞受體2:開發中產品分析

Hepatitis A Virus Cellular Receptor 2 - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 368708
出版日期 內容資訊 英文 83 Pages
訂單完成後即時交付
價格
A型肝炎病毒細胞受體2:開發中產品分析 Hepatitis A Virus Cellular Receptor 2 - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 83 Pages
簡介

本報告提供以A型肝炎病毒細胞受體2為標的治療藥之開發平台現狀及最新更新的各開發階段比較分析,提供您附最新的新聞和發表之企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

A型肝炎病毒細胞受體2 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Aurigene Discovery Technologies Limited
  • BeiGene, Ltd.
  • Eli Lilly and Company
  • Enumeral Biomedical Holdings, Inc.
  • Incyte Corporation
  • Interprotein Corporation
  • Jounce Therapeutics, Inc.
  • Novartis AG
  • Sorrento Therapeutics, Inc.
  • Sutro Biopharma, Inc.
  • Symphogen A/S
  • Tesaro, Inc.

藥物簡介

暫停中的計劃

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2145TDB

Summary

Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Hepatitis A virus cellular receptor 2 (HAVCR2) is a protein encoded by the HAVCR2 gene. It inhibits T-helper type 1 lymphocyte (Th1)-mediated auto- and alloimmune responses and promotes immunological tolerance. Binding to LGALS9 is proposed to be involved in innate immune response to intracellular pathogens and suppression of T-cell responses the resulting apoptosis of antigen-specific cells implicate HAVCR2 phosphorylation and disruption of its association with BAG6.

Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) pipeline Target constitutes close to 25 molecules. Out of which approximately 24 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 4, 5, 1, 7 and 7 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology and Infectious Disease which include indications Solid Tumor, Melanoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Advanced Malignancy, Bladder Cancer, Colon Cancer, Gastric Cancer, Glioblastoma Multiforme (GBM), Gliosarcoma, Head And Neck Cancer, Hematological Tumor, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Lymphoma, Malignant Mesothelioma, Metastatic Melanoma, Myelodysplastic Syndrome, Ovarian Cancer, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Primary Myelofibrosis, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Small-Cell Lung Cancer and Triple-Negative Breast Cancer (TNBC).

The latest report Hepatitis A Virus Cellular Receptor 2 - Pipeline Review, H2 2019, outlays comprehensive information on the Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2)
  • The report reviews Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Overview
  • Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Companies Involved in Therapeutics Development
  • Arbele Ltd
  • Aurigene Discovery Technologies Ltd
  • BeiGene Ltd
  • Bristol-Myers Squibb Co
  • Eli Lilly and Co
  • F. Hoffmann-La Roche Ltd
  • GigaGen Inc
  • GlaxoSmithKline Plc
  • Hutchison MediPharma Ltd
  • Immutics Inc
  • Incyte Corp
  • Interprotein Corp
  • Jiangsu Hengrui Medicine Co Ltd
  • Johnson & Johnson
  • Leads Biolabs Inc
  • Leidos Health
  • Ligand Pharmaceuticals Inc
  • Novartis AG
  • Shanghai Henlius Biotech Inc
  • Sutro Biopharma Inc
  • Symphogen A/S
  • Trellis Bioscience Inc
  • Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Drug Profiles
  • Antibody to Inhibit TIM3 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BGBA-425 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Bispecific Monoclonal Antibody to Inhibit PD1 and TIM3 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BMS-986258 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CA-170 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CA-327 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • cobolimab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HLX-52 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • INCAGN-2390 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • JNJ-8120 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LBL-003 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LY-3321367 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MGB-453 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Monoclonal Antibodies to Inhibit TIM-3 for Advanced Malignancy - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Monoclonal Antibodies to Inhibit TIM-3 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Monoclonal Antibody to Inhibit CD366 for Melanoma - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Monoclonal Antibody to Inhibit HAVCR2 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Monoclonal Antibody to Inhibit HAVCR2 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Peptides to Antagonize TIM3 for Oncology and Infectious Diseases - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RO-7121661 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SHR-1702 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit TIM-3 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Sym-023 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Synthetic Peptides to Inhibit TIM-3 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TRL-6061 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Dormant Products
  • Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Discontinued Products
  • Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Product Development Milestones
  • Featured News & Press Releases
  • Dec 02, 2019: Novartis to present abstract on MBG453 at American Society of Hematology Annual Meeting & Exposition (ASH) 2019
  • Aug 06, 2019: Curis provides update on development of mesothelioma drug candidate CA-170
  • May 06, 2019: Curis completes mesothelioma enrollment in CA-170 study
  • Jan 24, 2019: Curis: First Mesothelioma Patient Dosed in CA-170 Study
  • Nov 09, 2018: TESARO presents data on TSR-022 at SITC 2018 annual meeting
  • Oct 01, 2018: TESARO announces data presentation on its melanoma drug candidate TSR-022 at the SITC 2018 Annual Meeting
  • Jul 10, 2018: Selexis provides update on antibody candidate Sym023
  • Apr 11, 2018: Agenus Presents preclinical data on INCAGN02390 at the American Association for Cancer Research (AACR) 2018 Annual Meeting
  • Nov 03, 2017: Curis to Present Data On Its Cancer Drug Candidate CA-170 at the Society for Immunotherapy of Cancer 32nd Annual Meeting and the Cowen IO NEXT Summit
  • Nov 03, 2017: Curis to Present Preclinical Data On Its Cancer Drug candidate CA-327 at the Society for Immunotherapy of Cancer 32nd Annual Meeting and the Cowen IO NEXT Summit
  • Sep 11, 2017: Curis and Aurigene Announce CA-170 Program Update Following Data Presented at ESMO 2017
  • Aug 31, 2017: Curis Announces CA-170 Poster Presentation at ESMO 2017 Congress
  • May 25, 2017: Curis Announces Presentation on CA-170 at 2017 ASCO Annual Meeting
  • Nov 09, 2016: Curis Presents Early Clinical Pharmacokinetic and Biomarker Data from CA-170's Phase 1 Trial at the SITC 2016 Conference
  • Oct 11, 2016: Curis Expands Oncology Pipeline with an Oral Small Molecule PD-L1/TIM-3 Immune Checkpoint Antagonist
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..1)
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Arbele Ltd, H2 2019
  • Pipeline by Aurigene Discovery Technologies Ltd, H2 2019
  • Pipeline by BeiGene Ltd, H2 2019
  • Pipeline by Bristol-Myers Squibb Co, H2 2019
  • Pipeline by Eli Lilly and Co, H2 2019
  • Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
  • Pipeline by GigaGen Inc, H2 2019
  • Pipeline by GlaxoSmithKline Plc, H2 2019
  • Pipeline by Hutchison MediPharma Ltd, H2 2019
  • Pipeline by Immutics Inc, H2 2019
  • Pipeline by Incyte Corp, H2 2019
  • Pipeline by Interprotein Corp, H2 2019
  • Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2019
  • Pipeline by Johnson & Johnson, H2 2019
  • Pipeline by Leads Biolabs Inc, H2 2019
  • Pipeline by Leidos Health, H2 2019
  • Pipeline by Ligand Pharmaceuticals Inc, H2 2019
  • Pipeline by Novartis AG, H2 2019
  • Pipeline by Shanghai Henlius Biotech Inc, H2 2019
  • Pipeline by Sutro Biopharma Inc, H2 2019
  • Pipeline by Symphogen A/S, H2 2019
  • Pipeline by Trellis Bioscience Inc, H2 2019
  • Dormant Projects, H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019